Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar 17;25(3):304-17.
doi: 10.1016/j.ccr.2014.01.021.

Mutant p53 in cancer: new functions and therapeutic opportunities

Patricia A J Muller  1 , Karen H Vousden  2
Affiliations
Review

Mutant p53 in cancer: new functions and therapeutic opportunities

Patricia A J Muller et al. Cancer Cell. .

Abstract

Many different types of cancer show a high incidence of TP53 mutations, leading to the expression of mutant p53 proteins. There is growing evidence that these mutant p53s have both lost wild-type p53 tumor suppressor activity and gained functions that help to contribute to malignant progression. Understanding the functions of mutant p53 will help in the development of new therapeutic approaches that may be useful in a broad range of cancer types.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Strategies that Are Currently Being Explored to Target Mutant p53 Depicted in red are schematics of the strategies that are currently being explored to target p53 mutant-expressing cancers. These strategies include promotion of mutant p53 degradation through the proteasome and autophagy pathways, restoration of wild-type p53 activity, interference with the interaction between mutant p53 and other proteins, and interference in signaling pathways downstream of mutant p53.
See this image and copyright information in PMC

References

    1. Acin S., Li Z., Mejia O., Roop D.R., El-Naggar A.K., Caulin C. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J. Pathol. 2011;225:479–489. - PMC - PubMed
    1. Addadi Y., Moskovits N., Granot D., Lozano G., Carmi Y., Apte R.N., Neeman M., Oren M. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res. 2010;70:9650–9658. - PMC - PubMed
    1. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M.B., Guzzardo V. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009;137:87–98. - PubMed
    1. Agapova L.S., Ilyinskaya G.V., Turovets N.A., Ivanov A.V., Chumakov P.M., Kopnin B.P. Chromosome changes caused by alterations of p53 expression. Mutat. Res. 1996;354:129–138. - PubMed
    1. Ali A., Wang Z., Fu J., Ji L., Liu J., Li L., Wang H., Chen J., Caulin C., Myers J.N. Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nature communications. 2013;4:2667. - PMC - PubMed

Publication types

Substances